Illumina Aktie News

With Illumina's divestiture of GRAIL, the company will improve its operating expenses, since GRAIL reported significant losses while it was part of Illumina. The global DNA sequencing market is expected to grow at a CAGR of 9% from 2024 and 2028, which is a positive aspect for Illumina. Illumina has reported higher gross profit margins than its peers, which reflects that its core business is pr...

SAN DIEGO , July 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2025 following the close of market on Thursday, July 31, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, ...

Illumina was also recognized as one of the Best Companies to Work For byU.S. News & World Report SAN DIEGO , July 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced two awards recognizing the company's leadership in sustainability practices and as an employer of choice. TIME named Illumina to its World's Most Sustainable Companies list for the second year in a row, and U.S. N...

Key Points in This Article: Cathie Wood's ARK Innovation ETF (ARKK) has seen a mixed performance over the past five years, reflecting her high-risk, high-reward focus on disruptive technologies to prosper over time.

Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO , June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive ...

It's the insiders that know their company the best. And if they're willing to put their money where their mouths are, you may want to pay attention to why.

BALTIMORE--(BUSINESS WIRE)--Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing round. The round was led by Illumina Ventures, with participation from PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund. As part of the strategic plan to broaden its suite of service of...

SAN DIEGO , June 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), aligned with its commitments to advance the power of genomics, today published its annual Corporate Social Responsibility (CSR) Report. The report spotlights the ways Illumina is making precision health more accessible than ever before, and its ongoing work to empower people and communities, embed sustainability across its ...